Literature DB >> 12036082

Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Stephen R Lincoln1, Michael S Opsahl, Keith L Blauer, Susan H Black, Joseph D Schulman.   

Abstract

PURPOSE: To assess the effectiveness of outpatient treatment of Ovarian Hyperstimulation Syndrome associated with ascites.
METHODS: Forty-eight patients diagnosed with ovarian hyperstimulation and ascites from 2,246 consecutive in vitro fertilization cycles were retrospectively studied. Patients were treated with outpatient transvaginal culdocentesis and rehydration with intravenous crystalloids and albumin every 1-3 days until resolution of symptoms or hospitalization was required. Outcomes measured included incidences of hospitalization, pregnancy outcomes, cycle characteristics, and oocyte donors versus nondonors comparisons.
RESULTS: No complications occurred from outpatient treatments, and 91.6% of patients avoided hospitalization. The pregnancy rate in patients undergoing transfer was 84.7%, and the spontaneous loss rate was 16%. Overall, the estradiol on day of hCG was 4331 pg/mL (range 2,211-8,167), ascites removed was 1910 cm3 (122-4,000), and number of outpatient treatments was 3.4 (1-14). Nondonors averaged more outpatient treatments than donors (3.97 vs. 1.85), but similar rates of hospitalization (3/35 vs. 1/13).
CONCLUSIONS: Outpatient treatment consisting of culdocentesis, intravenous rehydration, and albumin minimized the need for hospitalization in hyperstimulated patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036082      PMCID: PMC3455652          DOI: 10.1023/a:1014828027282

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  21 in total

Review 1.  Ovarian hyperstimulation syndrome: an update review.

Authors:  A Golan; R Ron-el; A Herman; Y Soffer; Z Weinraub; E Caspi
Journal:  Obstet Gynecol Surv       Date:  1989-06       Impact factor: 2.347

2.  Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization.

Authors:  A Tollan; N Holst; F Forsdahl; H O Fadnes; P Oian; J M Maltau
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

3.  Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome.

Authors:  M A Aboulghar; R T Mansour; G I Serour; Y Amin
Journal:  Fertil Steril       Date:  1990-05       Impact factor: 7.329

4.  Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy.

Authors:  M A Aboulghar; R T Mansour; G I Serour; M A Sattar; Y M Amin; I Elattar
Journal:  Obstet Gynecol       Date:  1993-01       Impact factor: 7.661

Review 5.  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.

Authors:  D Navot; P A Bergh; N Laufer
Journal:  Fertil Steril       Date:  1992-08       Impact factor: 7.329

6.  Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization.

Authors:  J Smitz; M Camus; P Devroey; P Erard; A Wisanto; A C Van Steirteghem
Journal:  Hum Reprod       Date:  1990-11       Impact factor: 6.918

7.  Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach.

Authors:  R Borenstein; U Elhalah; B Lunenfeld; Z S Schwartz
Journal:  Fertil Steril       Date:  1989-05       Impact factor: 7.329

8.  The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome.

Authors:  R H Asch; G Ivery; M Goldsman; J L Frederick; S C Stone; J P Balmaceda
Journal:  Hum Reprod       Date:  1993-07       Impact factor: 6.918

9.  In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET Registry. Medical Research International. Society for Assisted Reproductive Technology (SART), The American Fertility Society.

Authors: 
Journal:  Fertil Steril       Date:  1992-01       Impact factor: 7.329

10.  Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome.

Authors:  D Navot; E J Margalioth; N Laufer; A Birkenfeld; A Relou; A Rosler; J G Schenker
Journal:  Fertil Steril       Date:  1987-07       Impact factor: 7.329

View more
  7 in total

1.  Safe motherhood in the United States: challenges for surveillance.

Authors:  Trude A Bennett; Melissa M Adams
Journal:  Matern Child Health J       Date:  2002-12

2.  Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.

Authors:  John M Csokmay; Belinda J Yauger; Melinda B Henne; Alicia Y Armstrong; John T Queenan; James H Segars
Journal:  Fertil Steril       Date:  2008-11-05       Impact factor: 7.329

Review 3.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

4.  Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.

Authors:  Michael M Alper; Laura P Smith; Eric Scott Sills
Journal:  J Exp Clin Assist Reprod       Date:  2009-06-10

Review 5.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

Review 6.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

7.  Outpatient Management of Severe Ovarian Hyperstimulation Syndrome (OHSS) with Placement of Pigtail Catheter.

Authors:  M Abuzeid; H Warda; S Joseph; M G Corrado; Y Abuzeid; M Ashraf; B Rizk
Journal:  Facts Views Vis Obgyn       Date:  2014
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.